Vaccines - Cambodia

Cambodia

The Vaccines market in Cambodia is expected to witness significant growth in the coming years.
According to projections, the revenue is projected to reach US$39.78m by 2024.
Furthermore, the market is anticipated to display a compound annual growth rate (CAGR 2024-2029) of -9.24%, leading to a market volume of US$24.50m by 2029.
When compared globally, it is noteworthy that United States is poised to generate the highest revenue in the Vaccines market, with an estimated value of US$29,120.00m in 2024.
Cambodia is experiencing an increasing demand for vaccines due to the government's efforts to improve healthcare infrastructure.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Cambodia has been increasing steadily in recent years.

Customer preferences: Cambodia has a young population with a high birth rate, which has led to an increase in demand for vaccines in the country. Additionally, the government has been actively promoting vaccination programs to improve public health.

Trends in the market: The vaccines market in Cambodia has been growing due to the increasing demand for preventive healthcare. The market is dominated by multinational companies, but there is also a growing presence of local manufacturers. However, the market is still largely reliant on imports.

Local special circumstances: Cambodia has a limited healthcare infrastructure, which has led to challenges in the distribution of vaccines. The country also faces issues related to vaccine storage and transportation due to its hot and humid climate. Furthermore, there is a lack of awareness and education among the population regarding vaccines.

Underlying macroeconomic factors: Cambodia has been experiencing steady economic growth in recent years, which has led to an increase in disposable income and an improvement in living standards. This has resulted in an increase in demand for healthcare services, including vaccines. Additionally, the government has been investing in the healthcare sector, which has led to an improvement in healthcare infrastructure and services.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.